47 results about "Dyskinesia" patented technology

The invention discloses a Parkinson's dyskinesia individualized SCAN network positioning method based on a multi-modal image and deep learning. The method comprises the steps of obtaining multi-modal medical image data, preprocessing the multi-modal medical image data, obtaining a multi-modal structure image and functional connection data, and calculating a spontaneous neural activity index of a whole-brain voxel level; taking a priori brain region related to the spontaneous neural activity index and dyskinesia as a seed point, constructing a seed point voxel function connection graph representing individual brain function connection, and performing nonlinear feature fusion and extraction through the deep learning network model; the bilinear attention network is adopted to capture the interaction information of the feature data and the individual dyskinesia symptom which is significantly related, an individualized SCAN network positioning result is obtained, the structure-function coupling characteristics of the individual brain are comprehensively described, the cross-modal pathological features related to the dyskinesia can be more sensitively recognized, and the accuracy and accuracy of the diagnosis and treatment of the dyskinesia can be improved. And the accuracy and robustness of abnormal brain region detection are obviously improved.

The application relates to the medical technical field, in particular to application of neoline in treatment of Parkinson's disease. 19 The C 19 The type-II diterpene alkaloid neoline can significantly improve movement disorder in a MPTP-induced Parkinson's disease model mouse, the drug efficacy is equivalent to that of the positive drug madopar, the effective dose is much lower than that of the positive drug, the administration mode is oral administration, drug compliance and use convenience are good, and the neoline can be used for development of anti-Parkinson's disease drugs.

The invention discloses a flexible shoulder rehabilitation exoskeleton based on a pneumatic folding driver, and the flexible shoulder rehabilitation exoskeleton comprises a trunk module, a shoulder module, a connecting assembly, a flexible folding pneumatic driving module, a multi-mode sensing module and a control terminal. By introducing the design of alternating internal folding and external folding, geometric dislocation between the driver and the joint axis is effectively compensated, and continuous high output torque is provided. The control system recognizes the motion intention of a user by collecting surface electromyogram signals and inertia measurement data through threshold judgment logic, and adjusts an electromagnetic proportional valve through a PID algorithm in combination with feedback of an air pressure sensor to achieve closed-loop accurate control over air pressure. The device has the advantages of light weight, high wearing comfort and excellent mechanical transparency, muscle load in rehabilitation training can be remarkably reduced, and the device is suitable for daily assistance and rehabilitation training of patients suffering from upper limb dyskinesia.

Pharmaceutical compositions comprising tartrate salts of medopredane and methods for making the pharmaceutical compositions are provided. The pharmaceutical composition is useful in the treatment of diseases such as L-DOPA induced dyskinesia.

Disclosed are compounds of formula (I) wherein G1 is as antagonists of the muscarinic acetylcholine receptor M4 (mAChR M4) for use in the treatment of e.g. a neurodegenerative disorder, a movement disorder, or a brain disorder, such as e.g. Parkinson's disease, drug-induced Parkinsonism, dystonia, Tourette's syndrome, dyskinesias, schizophrenia, cognitive deficits associated with schizophrenia, excessive daytime sleepiness, attention deficit hyperactivity disorder (ADHD), Huntington's disease, chorea, cerebral palsy, and progressive supranuclear palsy. An exemplary compound is e.g. (2,5-difluoro-4-(6-(((3aR,5s,6aS)-2-((tetrahydro-2H-pyran-4-yl)methyl)octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)phenyl)(imino)(methyl)-λ6-sulfanone (e.g. example 12; compound no. 7) Pharmacological data on the activity of the compounds in an mAChR M4 cell-based assay are provided (e.g. table 2).TABLE 2Human M4Cpd. No.IC50 (nM)Emin (%)*113.44239.62318.5345846575.4361883746.0385607918.43101.821186.231243.42138.63*% ACh maximum at 30 μM.

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without limitation, the epithelium (the goblet cells, ciliated pseudostratified columnar epithelial cells, and basal cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The system may be used to treat a variety of pulmonary diseases or disorders such as or associated with COPD (e.g., chronic bronchitis, emphysema), asthma, interstitial pulmonary fibrosis, cystic fibrosis, bronchiectasis, primary ciliary dyskinesia (PCD), acute bronchitis and / or other pulmonary diseases or disorders.

The present disclosure relates to compositions and methods for the treatment of dyskinesia using a pharmaceutical composition comprising 3-methylmethcathinone (3MMC), or a pharmaceutically acceptable salt thereof.

The invention discloses a Parkinson's disease dyskinesia recognition system based on cross-frequency coupling tensor decomposition, and the system comprises a signal collection and processing module which is used for synchronously collecting and preprocessing local field potential signals of multiple sites of a brain; the cross-frequency coupling calculation module is used for calculating a cross-frequency coupling map of each data slot; the signal-to-noise ratio balance processing module is used for generating an average cross-frequency coupling map of each tested individual; the tensor decomposition feature extraction module is used for aggregating the average cross-frequency coupling maps of all the tested individuals, constructing a third-order tensor and decomposing the third-order tensor to obtain three tensor components; moreover, when the average cross-frequency coupling atlas of the tested individual to be tested is input, weight vectors corresponding to the three tensor components are output; and the classification and identification module is used for inputting the weight vector of the tested individual to be tested into a pre-trained machine learning classification model and outputting an identification result of the dyskinesia of the Parkinson's disease. According to the method, the problem of frequency drift existing among different individuals can be solved, and the recognition accuracy is improved.

Apparatus and methods for utilizing a soft robot to facilitate standing and / or walking of pediatric patients, particularly patients suffering from dyskinesia, such as cerebral palsy. Such a soft robotic device may include a fabric pneumatic actuator that, upon inflation, generates the necessary torque along upper and lower contacts of the device to assist in movement of the patient, particularly in joint extension walking, standing, or sitting-to-standing movement. Compared with a fabric pneumatic actuator with an upright or isotropic structure, the concave structure can provide a larger torque angle and can also avoid friction and extrusion generated at the glenoid fossa. The actuator is soft, light in mass, good in compliance, and capable of providing comfortable joint extension in a multi-center trajectory. The actuator can be incorporated into a joint protector or an exoskeleton, and is very suitable for sensitive, soft and weak pediatric patients with dyskinesia, especially infants with cerebral palsy.

The invention relates to the technical field of medicines, in particular to application of songorine in treatment of Parkinson's disease. The C20-type diterpenoid alkaloid songnin provided by the invention can obviously and continuously improve dyskinesia caused by dopaminergic neuron injury in MPTP-induced Parkinson's disease model mice, and the onset dose of songnin is obviously lower than that of clinically common positive medicine, namely medoxolane, so that the songnin shows a stronger drug effect and can be used for preparing drugs for treating Parkinson's disease. The compound can be developed into a novel efficient anti-Parkinson disease treatment medicine.

The invention relates to the technical field of dyskinesia, in particular to application and a system of a gene marker combination in preparation of a Parkinson's disease dyskinesia risk assessment product, and the gene marker combination comprises COMT rs4680, MAOB rs1799836, GBA, DRD2 rs2283265, DRD3 rs6280, LRRK2 G2385R, BDNF rs6265, HOMER1 rs4704559 and SLC6A3 rs28363170. Wherein the product is used for calculating the dyskinesia risk value by detecting the genotype of the gene marker. According to the method, nine genetic markers and multi-modal clinical data are integrated, the risk probability is dynamically calculated based on the Bayesian algorithm, an individual intervention scheme is output, and early-stage accurate prevention and control are achieved.

The invention relates to an isotope labeled trapidil derivative. In particular, isotope labeled trapidil derivatives useful in the treatment of Parkinson's disease and dyskinesia associated with Parkinson's disease are provided. The isotope labeled trapidil derivative comprises a deuterated trapidil derivative. In addition, combination therapies of isotopically labeled trapidil derivatives and additional therapeutic agents for the treatment of Parkinson's disease and dyskinesia associated with Parkinson's disease are also provided.

The invention discloses an intent recognition system and method for disabled old people based on gaze and environment interaction, and belongs to the technical field of intelligent old people care and artificial intelligence. The invention aims to solve the problem of difficult communication of disabled old people caused by language and dyskinesia. The system comprises a multi-modal data acquisition unit which is used for acquiring staring target sequences and multi-dimensional situation information such as physiology, time, space and the like of old people; the situation feature fusion and construction unit is used for integrating the multi-source heterogeneous data into structured comprehensive situation representation; the core of the intention reasoning unit is a large language model, and the intention reasoning unit is used for carrying out deep semantic understanding and logical reasoning on the comprehensive situation and generating a candidate intention list with confidence; and the man-machine interaction output unit is used for presenting the recognition result to nursing personnel. According to the method, the staring behaviors and the rich situation information are deeply fused, the powerful reasoning ability of the large language model is utilized, the complex and dynamic intentions of the disabled old people can be accurately recognized in a natural and low-cognitive-load mode, and the communication efficiency and the nursing quality are remarkably improved.

The invention relates to a probiotic cocktail medical food composition and application thereof in delaying the progress of Parkinson's disease. The composition comprises (a) at least one probiotic with a neuroprotection or metabolism regulation function; (b) a functional amino acid combination, wherein the functional amino acid combination comprises four or more kinds of essential amino acid. The composition can be prepared into a medical food formula, is suitable for improving or relieving pathological changes such as dyskinesia, cognitive degeneration, inflammatory response and granulocyte function imbalance related to the Parkinson's disease, and can be used for daily nutrition supplement and disease progress delay of patients with the Parkinson's disease or high-risk groups.

The invention relates to the technical field of medicines, and discloses six adeno-associated virus (AAV) injections carrying novel artificial chemical genetics receptor gene sequences, and a combinatorial chemical genetics scheme formed by the injections and a small molecule agonist quetiapine. Compared with the traditional chemical genetics, the medicine quetiapine with smaller clinical side effect is used as the activating agent for the first time, and a novel chemical genetics system with lower medication risk is developed. The system can effectively reduce the excitatory activity of neurons, avoids the medication risk caused by clozapine or other non-market traditional chemical genetics activators, and improves the feasibility of clinical transformation of the chemical genetics system. In the aspect of application of a novel or traditional chemical genetics system, the combined treatment scheme is applied to intervene in Parkinson's disease (PD) for the first time, abnormal activities of STN and related loops of PD patients can be inhibited, and the dyskinesia symptom can be remarkably improved.

The invention relates to the technical field of transcranial magnetic stimulation, in particular to a transcranial magnetic stimulation system and method controlled by electroencephalogram signals. The system comprises an electroencephalogram acquisition module, a self-adaptive signal processing module, a dynamic stimulation control module, a reconfigurable transcranial magnetic stimulation module and a closed-loop feedback regulation module. The method comprises the following steps: collecting and preprocessing electroencephalogram signals of a subject; extracting multi-dimensional electroencephalogram features by combining wavelet packet decomposition and Hilbert-Huang transform through denoising of an improved U-Net model fused with physiological priori; dynamically optimizing stimulation parameters based on a particle swarm optimization algorithm; magnetic field focusing is realized by using a flexible coil array, and synchronous stimulation pulses are output by combining a phase locking mechanism; closed-loop feedback adjustment ensures that the stimulation effect reaches the standard. The problems that a traditional system is low in electroencephalogram analysis precision, poor in parameter adaptability, insufficient in focusing and low in synchronization precision are solved, the nerve regulation and control effect is improved, the damage risk of a non-target brain region is reduced, and the method is suitable for personalized treatment of nerve diseases such as depression and dyskinesia after cerebral apoplexy.

The application discloses a Parkinson's disease dyskinesia identification system based on cross-frequency coupling tensor decomposition, comprising: a signal acquisition and processing module, which is used for synchronously collecting local field potential signals of multiple sites of the brain and performing pretreatment; a cross-frequency coupling calculation module, which is used for calculating a cross-frequency coupling atlas of each data segment; a signal-to-noise ratio balance processing module, which is used for generating an average cross-frequency coupling atlas of each subject; a tensor decomposition feature extraction module, which is used for aggregating the average cross-frequency coupling atlas of all subjects, constructing a third-order tensor, and decomposing to obtain three tensor components; and when the average cross-frequency coupling atlas of a to-be-tested subject is input, a weight vector corresponding to the three tensor components is output; and a classification and identification module, which is used for inputting the weight vector of the to-be-tested subject into a pre-trained machine learning classification model, and outputting an identification result of Parkinson's disease dyskinesia. The application can overcome the frequency drift problem existing between different individuals and improve the identification accuracy.

Disclosed is a synthetic, non-naturally occurring 12-amino acid peptide, Lung-specific Targeting Peptide, belonging to the larger class of cell penetrating peptides, for delivery of both diagnostic and potentially therapeutic agents to the lung. Also disclosed are methods of treating pulmonary disease, e.g., chronic obstructive pulmonary disease (COPD), emphysema, chronic bronchitis, asthma, primary ciliary dyskinesia (PCD), cystic fibrosis (CF), and lung cancer.

This document describes a combination composition of compound 1 and fesoterodine for treating neurological disorders (e.g., schizophrenia, Alzheimer's disease psychosis, Parkinson's disease psychosis, cognitive impairment in Alzheimer's disease, psychosis in Lewy body dementia, bipolar disorder, and dyskinesia).

Provided are methods for delivering lipid nanoparticles (LNPs) to a lung cell of a subject suffering from or at risk for primary ciliary dyskinesia (PCD), wherein the method comprises nebulizing a liquid pharmaceutical composition to generate an aerosolized pharmaceutical composition, and administering the aerosolized pharmaceutical composition to the subject.

The present application belongs to the field of life science, and particularly relates to a functional probiotic strain Pediococcus pentosaceus. The Pediococcus pentosaceus WMU002 strain of the present application is derived from human body, and is high in safety after screening, domestication and verification. The Pediococcus pentosaceus WMU002 strain selected by the present application can obviously improve the motor disorder caused by Parkinson's disease and improve the behavior ability, overcome the defects and deficiencies of the prior art, and creatively apply the Pediococcus pentosaceus to the prevention and treatment of Parkinson's disease, and further develop a probiotic preparation for preventing or treating Parkinson's disease. The Pediococcus pentosaceus preparation composition of the present application can be used as a drug for preventing and treating Parkinson's disease, has no toxic side effects, and can be used for the auxiliary treatment of clinical Parkinson's disease patients. The present application has good social and economic benefits, and is worth popularization and application.

A fused ring compound of formula I, a pharmaceutical composition comprising same, a preparation method, a use for preventing and treating GPR6 receptor-mediated related diseases, such as movement disorders including Parkinson's disease, levodopa-induced dyskinesias, and Huntington's disease, drug addiction, eating disorders, cognitive disorders, schizophrenia, bipolar disorder, depression, etc., and a method.

The invention discloses a method for establishing a bee Parkinson's disease model based on characterization of dyskinesia and the like, which is characterized by comprising the following steps of: animal selection: selecting a mature bee as an object for establishing the bee Parkinson's disease model; preparing a modeling diet: preparing a sucrose solution containing casein hydrolysate and rotenone; and model establishment: feeding the mature bees with a modeling diet for 7 days to establish the bee Parkinson's disease model. The invention further discloses an application of the parkinson's disease model, established by the method, of the bacteria bees and / or the sterile bees. The method is easy and convenient to operate and low in cost, the motion distance and the motion speed of the built model bee are remarkably decreased, obvious dyskinesia is shown, and the survival rate of 5 days in an existing bee Parkinson model building technology is effectively increased to about 80% of 7 days from 5 days lower than 30%. The bee Parkinson's disease model established by the method can be used for screening new methods or new drugs for preventing or treating dyskinesia related diseases.

N-([1,1'-biaryl]-4-yl)-N-((1-hydroxycycloalkyl)methyl)-2-(aryl)cyclopropane-1-carboxamide compounds (I) and derivatives are G-protein coupled receptor (GPR) 88 modulators for use in the treatment of a disease mediated by GPR88. Indications include Tourette's Syndrome, Huntington's Disease (HD), Addiction, Parkinson's Disease (PD), Schizophrenia, and Attention Deficit Hyperactivity Disorder (ADHD), choreiform movements, tardive dyskinesia, speech delay, learning disabilities, depression, hyperkinetic movement disorders characterised by chorea and / or dystonia, psychosis, cognitive deficits in schizophrenia, affective disorders, bipolar disorder, Alzheimer's disease, basal ganglia disorders, and tardive dyskinesia.

The invention provides a free-moving mouse stomach nerve optical genetic manipulation and stomach movement synchronous recording system. The system comprises an optical genetic nerve manipulation module, a stomach movement detection module, a wireless energy supply and control module, a time synchronization module and a data acquisition and fusion module. A miniature LED light source, a bridge strain gauge sensor and a wireless energy receiving coil which are implanted in vivo are matched with an in-vitro wireless energy supply, time synchronization and data acquisition assembly, so that optical genetic activation / inhibition of gastric autonomic nerves and high-resolution capture of gastric movement signals are realized, and time alignment of the gastric autonomic nerves and the gastric movement signals is realized by outputting TTL (Transistor-Transistor Logic) pulses by virtue of a micro-control unit; according to the system, the mouse does not need to be fixed or anesthetized, the implanted component is excellent in biocompatibility, long-term continuous recording can be achieved, time synchronization is accurate, and key technical support is provided for analyzing a stomach autonomic nerve innervation mechanism, exploring the relation between stomach autonomic nerve abnormity and stomach dyskinesia, studying gastrointestinal tract disease pathogenesis and the like.

The invention discloses an isoindoline-1-ketone-containing compound and a pharmaceutical composition and application thereof, the structure of the compound is shown as a formula IA or IB, the compound has good inhibitory activity on MAGL, the optimal inhibition rate on the micromolar concentration level reaches 90% or above, the inhibitory activity IC50 value reaches the nanomolar concentration level, and the compound has good application prospects. The compound can be applied to preparation of drugs for preventing and / or treating diseases related to MAGL. Comprise depression, schizophrenia, bi-directional disorder, dyskinesia, traumatic brain injury, neuroinflammation, Parkinson's disease, Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis, anxiety disorder, pain, metabolic disorder, alcoholic fatty liver disease, non-alcoholic fatty liver disease, hepatic fibrosis, cholestasis, nephropathy and the like.

Provided herein are optionally substituted benzoimidazol-1,2-yl amides, pharmaceutical compositions comprising a therapeutically effective amount of such compounds and a pharmaceutically acceptable excipient, and methods of treating Kv7 associated diseases, such as, epilepsy, amyotrophic lateral sclerosis, various types of pain, hyperexcitability, a dyskinesia, dystonia, mania and tinnitus with such compounds and pharmaceutical compositions.

The present invention is directed to a method for treating primary ciliary dyskinesia (PCD) using a splicing modulator, such as an antisense oligonucleotide, capable of inducing the skipping of exon 3 of the coiled-coil domain containing 40 (CCDC40) pre-mRNA. Also provided is a composition comprising the splicing modulator, and use of same.

The invention relates to application of a Xiaji acupoint electroacupuncture in preparation of equipment for treating Parkinson's frozen gait, and belongs to the technical field of modernization of traditional Chinese medicine. A traditional Chinese medicine acupuncture technology and a modern electroacupuncture technology are combined, a new application of electroacupuncture is provided, electroacupuncture is adopted to stimulate a spine point area, an electric signal is transmitted to a center through anterior and posterior spines of spinal nerves, release of dopamine in a basal node is promoted, signal inhibition of a cortex auxiliary movement area is relieved, and the aim of treating the spines is achieved. Excitation input of anterior spinal horn motor neurons is increased, so that contraction of skeletal muscles is triggered, movement retardation and frozen gaits of Parkinson's disease patients are improved, pathological neural circuits of PD are rapidly broken, nerve functions are remodeled through long-term stimulation, and a new path is provided for drug or DBS refractory dyskinesia and frozen gaits.